Format

Send to

Choose Destination
Neuro Oncol. 2019 Oct 17. pii: noz191. doi: 10.1093/neuonc/noz191. [Epub ahead of print]

An independently validated survival nomogram for lower grade glioma.

Author information

1
Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.
2
Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
3
Department of Neurological Surgery, University Hospitals of Cleveland and Case Western University School of Medicine, Cleveland, Ohio.
4
Seidman Cancer Center, University Hospitals of Cleveland, Cleveland, Ohio.
5
University Hospitals Research Division, Cleveland, Ohio.
6
Cleveland Center for Health Outcomes Research (CCHOR), Case Western Reserve University School of Medicine, Cleveland, Ohio.

Abstract

BACKGROUND:

Gliomas are the most common primary malignant brain tumor. Diffuse low-grade and intermediate-grade gliomas, which together comprise the lower-grade gliomas [LGG] (WHO grades II and III), present a therapeutic challenge to physicians due to the heterogeneity of their clinical behavior. Nomograms are useful tools for individualized estimation of survival. This study aimed to develop and independently validate a survival nomogram for patients with newly diagnosed LGG.

METHODS:

Data were obtained for newly diagnosed LGG patients from The Cancer Genome Atlas (TCGA) and the Ohio Brain Tumor Study (OBTS) with the following variables: tumor grade (II or III), age at diagnosis, sex, Karnofsky Performance Status (KPS), and molecular subtype (IDH mutant with 1p/19q codeletion [IDHmut-codel], IDH mutant without 1p/19q codeletion [IDHmut-non-codel], IDH wild-type [IDHwt]). Survival was assessed using Cox proportional hazards regression, random survival forests, and recursive partitioning analysis, with adjustment for known prognostic factors. The models were developed using TCGA data and independently validated using the OBTS data. Models were internally validated using 10-fold cross-validation and externally validated with calibration curves.

RESULTS:

A final nomogram was validated for newly diagnosed LGG. Factors that increased the probability of survival included grade II tumor, younger age at diagnosis, having a high KPS, and the IDHmut-codel molecular subtype.

CONCLUSIONS:

A nomogram that calculates individualized survival probabilities for patients with newly diagnosed LGG could be useful to healthcare providers for counseling patients regarding treatment decisions and optimizing therapeutic approaches. Free online software for implementing this nomogram is provided: https://hgittleman.shinyapps.io/LGG_Nomogram_H_Gittleman/.

KEYWORDS:

Lower grade glioma; TCGA; glioma; nomogram; survival

PMID:
31621885
DOI:
10.1093/neuonc/noz191

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center